Aripiprazole ODT: another psychotropic medicine in form of orally-disintegrating tablets Review article
Article Sidebar
Main Article Content
Abstract
Aripiprazole, a partial dopamine agonist, is an antipsychotic drug with additional mood-stabilizing and antidepressant properties. Aripiprazole has been approved for the treatment of schizophrenia, bipolar disorder, and depression as an add-on treatment when the main antidepressant is not sufficiently effective. Aripiprazole is also used to treat symptoms of mood swings, aggression, and irritability associated with autistic disorders and Tourette’s syndrome in pediatric patients aged 6 or more. Aripiprazole uses a different mechanism than other drugs that have been approved for the same symptoms: while the majority of antipsychotics inhibit dopamine D2 receptors, aripiprazole balances the activity of these receptors. The ODT form of the drug recently made available in Poland provides additional advantages for the patients. ODT influences specific bioavailability (rapid absorption) due to pregastric absorption. The drug in this form is easy to swallow and as such it is convenient for young and elderly patients as well as not fully compliant patients.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Henderson DC, Fan X, Copeland PM et al. Aripiprazole added to Overweight and Obese Olanzapine-treated Schizophrenia Patients. J Clin Psychopharmacol 2009; 29(2): 165-169.
3. San L, Casillas M, Ciudad A, Gilaberte I. Olanzapine orally disintegrating tablet: a review of efficacy and compliance. CNS Neuroscience & Therapeutics 2008; 14: 208-214.
4. Łoza B. Olanzapina w formie tabletek rozpuszczających się w jamie ustnej: nowe możliwości terapeutyczne. Medycyna Faktów 2011; 4(1): 50-55.
5. Eslick GD, Talley NJ. Dysphagia: epidemiology, risk factors and impact on quality of life – a population-based study. Aliment Pharmacol Ther 2008; 2(10): 971-979.
6. Thakur RR, Kashi M. An unlimited scope for novel formulations as orally disintegrating systems: Present and future prospects. J Appl Pharm Sci 2011; 1(1): 13-19.
7. De Lucas-Taracena MT, Mntanes-Rada F. Fobia a tragar: clinica, diagnostic y tratamiento. Actas Esp Psiquiatr 2006; 34(5): 309-316.
8. Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmadodynamics: basic priciples and practical applications. Br J Clin Pharm 2003; 57(1): 6-14.
9. Palleria C, Di Paolo A, Giofrè C et al. Pharmacokinetic drug-drug interaction and their implication in clinical management. J Res Med Sci 2013; 18(7): 601-610.
10. Czekalla J, Wagner T, Schacht A et al. Effectiveness and medication acceptance of olanzapine disintegrating tablets compared to standard olanzapine tablets in acutely treated psychiatric patients. Patient Preferences and Adherence 2007; 1: 19-27.
11. Reeves RR, Torres RA. Orally disintegrating olanzapine for the treatment of psychotic and behavioral disturbances associated with dementia. Souther Medical Journal 2003; 96(7): 699-701.
12. Bitter I, Treuer T, Dilbaz N et al. Patients’ preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study. World J Biol Psych 2010; 11: 894-903.
13. Arranz B, San L, Duenas RM et al. Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients. Human Psychopharmacology 2007; 22: 11-15.
14. Kinon BJ, Hill AL, Liu H, Kollack-Walker S. Olanzapine orally disintegrating tablets in the treatment of acutely ill, non-compliant patients with schizophrenia. Int J Neuropsychopharmacol 2003; 6: 97-102.
15. Yi W, Tong L, Guoshuang Z, Hao L. A controlled study for aripiprazole orally disintegrating tablets and aripiprazole tablets in the treatment of schizophrenia. Tianjin Pharmacy 2008; 3: 47-49.
16. Román M, Ochoa D, Rivas A et al. Comparative bioavailability of aripiprazole tablets and orally disintegrating tablets in young healthy volunteers. Clinical Therapeutics 2015; 37(8): e143.
17. EMA, European Medicines Agency. EU/1/04/276/001-005. Data ostatniej rewizji: 04/2015.